Bladder cancer
A Smarter Urine Test for Bladder Cancer
As reported on Inside Precision Medicine, Researchers at Stanford have created a new urine test that helps doctors understand how well bladder cancer treatments are
Akebia Doses First Volunteers in Phase 1 Study of AKB-9090 for Surgery-Related AKI
- April 15, 2026
Triple Negative Breast Cancer: A Breakthrough Treatment
Combinatorial Immunotherapy Strategy: CatalYm Advances Visugromab in Advanced Liver Cancer
Litifilimab Shows Promise in Phase 2 Trial for Cutaneous Lupus
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
Muscular Dystrophy
Strategic Reassessment: Roche Discontinues Emugrobart in Spinal Muscular Atrophy and FSHD
Chugai Pharmaceutical Co., Ltd. announced that Roche has made the strategic decision to discontinue clinical development of GYM329 (emugrobart), an investigational anti-latent myostatin antibody, for
Thyroid eye disease
Amgen Reports Positive Phase 3 Data for Subcutaneous Tepezza in Thyroid Eye Disease
As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults
Cervical Dystonia
Living in Fear of Pain Can Make Pain Worse
Most of us have heard of the fight-or-flight stress response. It becomes activated when we believe there is a chance we can outfight or outrun
Triple-negative breast cancer
Revolutionary Approach to Triple-Negative Breast Cancer: Telomir-1 Advances Toward Clinical Trials
Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology’s most challenging cancers. As reported
Rare Disease
What Happens When a Patient Is Living with Multiple Rare Diseases?
I have battled several autoimmune and neurological conditions that are triggered by food and other factors for over 50 years. It took most of my
HIV/AIDS
Reimagining HIV Treatment: When Monthly Clinic Visits Outperform Daily Pills
The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model
Dermatomyositis
Phase 3 VALOR Trial Shows Brepocitinib Improves Outcomes in Dermatomyositis
As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal
Congestive Heart Failure
Can We Fix This Broken Heart? – Part 5
Editor’s Note: Patient Worthy is pleased to share the final part in a series of excerpts by Dana Langston. Chapter 36: Holding the Line Knowing
Primary Biliary Cholangitis
A Breakthrough for the Invisible Affliction: FDA Approves First-Ever Treatment for Cholestatic Itch in Liver Disease
For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch
Rare Disease
EMERALD‑3 Trial Shows Benefit of Dual Immunotherapy–Based Strategy in Embolization‑Eligible Liver Cancer
As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with
Congestive Heart Failure
Can We Fix This Broken Heart? – Part 4
Editor’s Note: Patient Worthy is pleased to share part 4 of 5 in a series of excerpts written by Dana Langston. Part 7: Legacy &
Major Depressive Disorder
Breaking Through Depression’s Barriers: Real-World Evidence Demonstrates Spravato’s Long-Term Effectiveness
When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants,
Thyroid eye disease
Subcutaneous Tepezza Matches Infusion in Phase 3 Trial, Amgen Reports
As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the
Rare Disease
Can We Fix This Broken Heart? – Part 3
Editor’s Note: Patient Worthy is proud to bring you part 3 of 5 in a series of excerpts written by Dana Langston. Part 3: The
Wet macular degeneration
Next-Generation Eye Treatment OLN324 Demonstrates Superior Performance in Major Clinical Trial
Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases
Narcolepsy
Alkermes Launches Phase 3 Program for Investigational Narcolepsy Therapy Alixorexton
As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people
Rare Disease
Can We Fix This Broken Heart? – Part 2
Editor’s Note: This is the second part in a series of excerpts written by Dana Langston. Chapter 4: The Internal Shift We are living in
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
Not every health issue is visible- and that's why awareness matters.
Oral cancer can start quickly, with small changes like a sore that won't heal, unusual lumps, or persistent pain. These signs are easy to overlook, but catching them early can make a life-saving difference.
This Oral Cancer Awareness Month, take a moment to check in with your health. Stay informed, keep up with dental visits, and don’t ignore what your body is trying to tell you. Awareness isn't just knowledge- it's prevention, action, and care. #OralCancerAwareness #OralHealth #PatientWorthy
Neurofibromatosis Network- CAMP can be an amazing experience for rare disease kids
United Leukodystrophy FoundationIn recognition of #NationalPublicHealthWeek, we’re honored to host the ULF Annual Scientific Symposium and Family Conference, taking place June 25–27, 2026.
This special gathering offers a meaningful opportunity to learn, collaborate, and connect within the leukodystrophy community. Whether you are a family impacted by leukodystrophy, a medical professional, or a researcher, the Symposium and Conference provide a welcoming space for education, shared insight, and empowerment. Register today: ulf.org/scientific-symposium-family-conference/ #ULFConference #Leukodystrophy
